Can You Have Fibroids and Polyps at the Same Time?

Having fibroids and polyps at the same time is not only possible but fairly common. Research on women undergoing surgery for uterine fibroids found that roughly one in five also had endometrial polyps, and certain factors like age, blood pressure, and the number of fibroids present made co-occurrence even more likely. The two growths are biologically distinct, arising from different tissue types and driven by different genetic changes, yet they share enough underlying risk factors that finding both in the same uterus is a routine clinical scenario rather than an unusual coincidence.

How Common Is the Overlap?

A study of 770 women who had hysterectomies for uterine fibroids found endometrial polyps in about 20% of them. That means one in five women who came in for fibroid-related problems also had polyps that may or may not have been diagnosed beforehand. The study identified several factors that raised the odds of having both conditions. Women aged 45 and older were roughly 60% more likely to have polyps alongside their fibroids. Those with high blood pressure had higher co-occurrence rates as well. Women who already had cervical polyps were about three times as likely to also harbor endometrial polyps, and those with endometrial hyperplasia (an overgrowth of the uterine lining) were four times as likely.

Interestingly, the relationship also correlated with fibroid characteristics. Women with two or more fibroids were more likely to have co-existing polyps than those with a single fibroid, and polyps appeared more often when the largest fibroid was under 8 centimeters. That last finding may seem counterintuitive, but smaller or more numerous fibroids can signal a uterine environment where multiple types of abnormal growth are being promoted simultaneously.

Why They Tend to Show Up Together

Fibroids and polyps are fundamentally different growths. Fibroids (leiomyomas) are masses of smooth muscle and connective tissue that grow within or around the uterine wall. Polyps are overgrowths of the endometrium, the glandular lining of the uterus. They look different under a microscope, and research into their genetic underpinnings confirms they originate through distinct mutations. One study examining a tissue sample initially thought to contain both a polyp and a fibroid found a MED12 gene mutation, a common driver of fibroid growth. Closer analysis showed the mutation was confined entirely to the fibroid tissue and absent from the polyp, confirming that the two growths arose independently even though they occupied the same uterus.

Despite being genetically unrelated, fibroids and polyps share key risk factors. Both are sensitive to estrogen, the hormone that drives growth in endometrial tissue and plays a role in fibroid development. Both become more common with age, particularly in the years approaching menopause when hormonal fluctuations are most pronounced. And both are linked to metabolic conditions. Research has found that being overweight and having high blood pressure significantly increase the risk of fibroids, while a separate study of postmenopausal women found that obesity, diabetes, and dyslipidemia all independently raised the odds of endometrial polyps. Women meeting the criteria for metabolic syndrome were roughly 2.8 times more likely to have polyps compared with those who did not.

³⁴

So the reason fibroids and polyps co-occur is less about one causing the other and more about a shared environment. A uterus exposed to prolonged estrogen stimulation, housed in a body carrying extra weight or managing metabolic issues, is fertile ground for both types of abnormal growth at once.

The Diagnostic Challenge

Finding one growth when two are present is a genuine clinical pitfall. Standard transvaginal ultrasound, the first-line imaging tool for evaluating the uterus, is decent at spotting fibroids but less reliable for polyps. One comparative study found that regular transvaginal ultrasound detected endometrial polyps with a sensitivity of about 61% and submucous fibroids with a sensitivity of about 57%. That means standard ultrasound missed roughly 40% of polyps and more than 40% of inner-cavity fibroids.

⁵

A more revealing approach is saline infusion sonohysterography, where sterile saline is gently pushed into the uterine cavity during ultrasound. The fluid outlines the inner surfaces and makes polyps and submucous fibroids stand out. In the same study, this technique raised sensitivity to 95% for polyps and nearly 97% for submucous fibroids, with virtually no false positives. If you have known fibroids and your doctor wants to rule out polyps, asking about sonohysterography is reasonable.

⁵

Hysteroscopy, where a thin camera is inserted directly into the uterus, is considered the gold standard for seeing what is inside the cavity. A systematic review confirmed that diagnostic hysteroscopy is both accurate and practical for identifying intrauterine abnormalities in women with abnormal bleeding. But it is not perfect either. A six-year study of diagnostic hysteroscopies found fibroids in about 21% of cases and polyps in about 14%, yet hysteroscopic appearance alone sometimes misclassified one as the other. In a handful of cases ultimately diagnosed as endometrial cancer, the initial hysteroscopic impression was of a benign polyp or fibroid. This is why tissue sampling (biopsy) during hysteroscopy is standard practice and why visual diagnosis alone can be misleading.

⁶⁷

When both conditions are present, one can mask the other on imaging. A large fibroid distorting the uterine wall may make a small polyp in the cavity harder to see, and vice versa. For women with heavy bleeding or fertility concerns who have already been diagnosed with fibroids, an evaluation that goes beyond basic ultrasound improves the chances of catching co-existing polyps.

How Symptoms Overlap and Compound

Both fibroids and polyps can cause abnormal uterine bleeding, which is the most common reason women end up being evaluated for either condition. Heavy periods, prolonged periods, bleeding between periods, and spotting after menopause can all point to fibroids, polyps, or both. When the two coexist, teasing apart which growth is responsible for your specific symptoms can be tricky, and in practice it often does not matter clinically because treatment addresses both.

There are some differences in symptom patterns. Fibroids, depending on their size and location, often cause pelvic pressure, a sense of fullness, urinary frequency, or constipation, none of which polyps typically produce. Polyps are usually smaller and more likely to cause irregular spotting rather than the drenching, prolonged periods characteristic of large fibroids. But a submucosal fibroid (one that bulges into the uterine cavity) and a large endometrial polyp can produce almost identical bleeding patterns, making clinical distinction without imaging unreliable.

What Both Conditions Mean for Fertility

If you are trying to conceive and have been diagnosed with fibroids, polyps, or both, the picture gets more complicated. Both conditions have been linked to impaired endometrial receptivity, the uterine lining’s ability to accept and support an implanted embryo. Research has found that polyps, fibroids, and adenomyosis are all associated with abnormal molecular patterns in the endometrium that may interfere with implantation and early embryo development.

⁸

Not all fibroids affect fertility equally. Submucosal fibroids, those that distort the uterine cavity, have the strongest association with reduced pregnancy rates. Fibroids that are entirely within the muscular wall (intramural) or on the outer surface (subserosal) may not interfere at all. Polyps are generally easier to address since they can be removed in a quick outpatient procedure, and removal often restores normal fertility potential when a polyp was the primary barrier. When both a submucosal fibroid and a polyp are present, your fertility specialist will typically want to remove both before proceeding with treatment, since the combined effect on the uterine environment is likely worse than either alone.

Treatment When Both Are Present

One advantage of having both conditions diagnosed simultaneously is that they can often be treated in a single procedure. Hysteroscopic surgery allows a gynecologist to enter the uterine cavity with a camera and instruments through the cervix, removing polyps and accessible fibroids without any abdominal incisions. A randomized study comparing two hysteroscopic techniques for removing intrauterine polyps and fibroids found that a morcellation device completed removals in an average of about 11 minutes compared with about 17 minutes for conventional resectoscopy, with both methods effective and no learning curve observed for the newer device.

⁹

When fibroids are too large or too numerous for hysteroscopic removal, surgical planning becomes more involved. Myomectomy (removing fibroids while preserving the uterus) through the abdomen remains an option, but it does not automatically address polyps in the uterine cavity. A staged approach, hysteroscopy for the polyps and cavity-based fibroids followed by a separate procedure for larger fibroids, is sometimes necessary. For women done with childbearing and dealing with severe symptoms from both conditions, hysterectomy eliminates the problem entirely.

On the medical side, certain drugs can manage bleeding from fibroids but do not directly treat polyps. Progestins and especially the levonorgestrel-releasing intrauterine system (a hormonal IUD) can reduce fibroid-related bleeding, prevent anemia, and improve quality of life, though they do not shrink fibroids or remove polyps. The medications most consistently shown to reduce both bleeding and fibroid volume are GnRH agonists and the newer oral GnRH antagonists, which work by suppressing estrogen production.

¹⁰

After surgical removal, recurrence is a real consideration with both conditions. A study of women who had abdominal myomectomy for large fibroids found that about 12% eventually chose to undergo a repeat uterine surgery for recurring symptoms.

¹¹

Tamoxifen and Developing Both Conditions

One medication deserves special mention because it is uniquely capable of triggering both fibroids and polyps. Tamoxifen, widely prescribed to women with estrogen receptor-positive breast cancer, acts as an estrogen blocker in breast tissue but has estrogen-like effects on the uterus. The result is a range of uterine changes including endometrial polyps (the most common tamoxifen-related uterine finding), endometrial thickening, hyperplasia, fibroid growth, and in rare cases, endometrial cancer.

¹²

One study found that tamoxifen significantly increased endometrial thickness and uterine volume within just three months, while also inducing new endometrial polyps and enlarging pre-existing fibroids.

¹³

The incidence of uterine abnormalities in women on tamoxifen ranges from about 8% to 36%, compared with up to 10% in untreated women. Several studies have shown fibroid growth specifically in postmenopausal patients on the drug, though the fibroids do not appear to be histologically different from those in untreated women.

¹⁴

If you are taking tamoxifen and develop abnormal bleeding or pelvic symptoms, prompt evaluation is warranted. The polyps that develop in tamoxifen users can be unusually large or numerous, and the heightened background risk of endometrial changes makes it important to distinguish benign growths from something more concerning.

When to Think About Cancer Risk

Fibroids are almost always benign. The overwhelming majority are ordinary leiomyomas that pose no cancer risk whatsoever. Uterine sarcoma arising from a fibroid is exceptionally rare, and there is no reliable way to distinguish a benign fibroid from the rare malignant variant on imaging alone, which is one reason rapid fibroid growth or unusual symptoms sometimes prompt surgery for definitive diagnosis.

Polyps carry a slightly different risk profile. While most endometrial polyps are benign, a small percentage harbor precancerous or cancerous cells, and certain features raise the odds. A study examining malignancy risk factors in endometrial polyps found that fasting blood glucose levels above a certain threshold carried a tenfold increase in cancer risk, while larger polyps and thicker endometrial linings were also associated with higher malignancy rates.

¹⁵

Postmenopausal bleeding is the most important red flag. Any bleeding after menopause warrants evaluation regardless of whether fibroids or polyps have already been diagnosed, because it may signal endometrial hyperplasia or cancer. Having known benign conditions can create a false sense of reassurance; women sometimes assume their bleeding is “just the fibroid” when in fact a polyp has undergone malignant change. This is especially relevant for women on tamoxifen or hormone replacement therapy, where the uterine environment is being actively stimulated.

Hormone Therapy After Menopause

Women who enter menopause with known fibroids sometimes worry about whether hormone replacement therapy (HRT) will make things worse. The evidence is mixed. A review of available studies found that HRT had variable effects on the volume and size of fibroids in menopausal women. Some studies showed that higher doses of progestogen in combination therapy increased the size of pre-existing asymptomatic fibroids and even triggered formation of new ones.

¹⁶

For polyps, the picture is similarly complicated. One study evaluating women on long-term continuous combined HRT found that discrepancies between imaging findings and tissue biopsy results were frequently associated with the presence of polyps and submucosal fibroids.

¹⁷

The practical takeaway for menopausal women with both conditions: HRT is not categorically off the table, but it does require closer monitoring. Your doctor may recommend periodic imaging or even hysteroscopy to keep an eye on both fibroids and the endometrial lining, particularly if you develop any new bleeding. The estrogen component in HRT can stimulate both types of growth, and knowing you already have a susceptible uterus shifts the risk-benefit conversation. For women with bothersome fibroids and polyps who are weighing HRT for menopausal symptoms, non-hormonal alternatives for hot flashes and other symptoms may be worth discussing as a way to avoid adding fuel to the fire.

1
PubMed Central. Prevalence of endometrial polyps coexisting with uterine fibroids and associated factors
2
British Journal of Cancer. Somatic MED12 mutations in uterine leiomyosarcoma and colorectal cancer
3
PubMed. Relationship between metabolic syndrome and uterine leiomyomas: a case-control study
4
PubMed. Metabolic syndrome as a predictor of endometrial polyps in postmenopausal women
5
PubMed Central. A Comparative Observational Study of the Use of Saline Uterine Hydrosonography for the Diagnosis and Assessment of Uterine Cavity Lesions in Women
6
PubMed. Diagnostic hysteroscopy in abnormal uterine bleeding: a systematic review and meta-analysis
7
PubMed. Diagnostic hysteroscopy: a valuable diagnostic tool in the diagnosis of structural intra-cavital pathology and endometrial hyperplasia or carcinoma?
8
ScienceDirect. Uterine polyps, adenomyosis, leiomyomas, and endometrial receptivity
9
PubMed. Hysteroscopic morcellator for removal of intrauterine polyps and myomas: a randomized controlled pilot study among residents in training
10
ScienceDirect. Abnormal uterine bleeding: The well-known and the hidden face
11
PubMed Central. Reoperation rates for recurrence of fibroids after abdominal myomectomy in women with large uterus
12
PubMed. Tamoxifen and the female reproductive tract
13
Annals of Oncology. Breast cancer Third generation aromatase inhibitors may prevent endometrial growth and reverse tamoxifen-induced uterine changes in postmenopausal breast cancer patients
14
PubMed Central. The effect of tamoxifen on the genital tract
15
PubMed Central. Malignancy risk factors based on endometrial polyp
16
Menopause. Hormone therapy in menopausal women with fibroids: is it safe?
17
European Journal of Obstetrics & Gynecology and Reproductive Biology. Endometrial status in post-menopausal women on long-term continuous combined hormone replacement therapy (Kliofem®)